Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ANTX
#3609
AN2 Therapeutics, Inc. Common Stock
1.1
0
+1.85%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+1.85%
Monthly Change
-7.56%
6 month change
-3.51%
Year Change
+0.92%
Previous Close
1.0
8
Open
1.1
0
Bid
Ask
Low
1.1
0
High
1.1
0
Volume
1
Markets
US Stock Market
Healthcare
ANTX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2022
2023
2024
TTM
Cash from operating activities
-33.46 M
-53.29 M
-49.26 M
-29.87 M
Cash from investing activities
-21.77 M
-43.28 M
54.59 M
14.26 M
Cash from financing activities
70.36 M
84.99 M
372 K
113 K
Free cash flow
-33.46 M
-53.29 M
-49.26 M
-29.87 M
News
AN2 Therapeutics appoints Sarah Williams as principal accounting officer
FDA clears IND for epetraborole trial in mycobacterium abscessus
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
An2 therapeutics (ANTX): cfo Day sells $8883 in shares
An2 therapeutics CSO prior sells $6507 in stock
Eizen, AN2 Therapeutics COO, sells $25k in ANTX stock
An2 therapeutics chief development officer sells $9k in stock
AN2 Therapeutics partners with GSK to develop TB treatments
Eizen Joshua M of AN2 Therapeutics sells $3213 in stock
Prior Stephen David, AN2 Therapeutics chief strategy officer, sells $872 in stock
AN2 Therapeutics doses first cohort in Phase 1 trial for Chagas disease